Merck, Inc.
🇺🇸United States
Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
Phase 3
Completed
- Conditions
- Bacterial Pneumonia
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2020-04-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 537
- Registration Number
- NCT02493764
A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)
Phase 2
Terminated
- Conditions
- Type II Diabetes Mellitus
- Interventions
- First Posted Date
- 2015-07-09
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 176
- Registration Number
- NCT02492763
Efficacy and Safety Study of RAGWITEK™ (MK-3641) in Children With Ragweed-Induced Rhinoconjunctivitis With or Without Asthma (MK-3641-008)
Phase 3
Completed
- Conditions
- Rhinitis, Allergic, Seasonal
- Interventions
- Biological: PlaceboBiological: Short ragweed pollen allergen extractDrug: Albuterol/Salbutamol
- First Posted Date
- 2015-06-23
- Last Posted Date
- 2019-09-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 1025
- Registration Number
- NCT02478398
A Study to Evaluate the Effects of Tedizolid Phosphate on the Pharmacokinetics and Safety of Midazolam and Rosuvastatin (MK-1986-004)
Phase 1
Completed
- Conditions
- Skin Diseases, Bacterial
- Interventions
- First Posted Date
- 2015-06-22
- Last Posted Date
- 2015-08-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 18
- Registration Number
- NCT02477514
The Effect of Antacids on the Pharmacokinetics (PK) of Raltegravir in Human Immunodeficiency Virus (HIV)-Infected Participants (MK-0518-824)
Phase 1
Completed
- Conditions
- HIV Infection
- Interventions
- First Posted Date
- 2015-06-16
- Last Posted Date
- 2018-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 20
- Registration Number
- NCT02473367
A Multiple-Dose Study to Evaluate MK-1075 in Hepatitis C Virus (HCV) Infected Participants (MK-1075-004)
Phase 1
Completed
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Drug: 400 mg MK-1075Drug: 800 mg MK-1075Drug: 200 mg MK-1075
- First Posted Date
- 2015-06-03
- Last Posted Date
- 2018-11-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT02461563
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
Phase 2
Completed
- Conditions
- Colorectal Carcinoma
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 124
- Registration Number
- NCT02460198
Study of Pembrolizumab (MK-3475) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma (MK-3475-087/KEYNOTE-087)
- First Posted Date
- 2015-05-25
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 211
- Registration Number
- NCT02453594
Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)
Phase 1
Completed
- Conditions
- Neutropenia
- Interventions
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 118
- Registration Number
- NCT02452034
Efficacy and Safety of Imipenem+Cilastatin/Relebactam (MK-7655A) Versus Colistimethate Sodium+Imipenem+Cilastatin in Imipenem-Resistant Bacterial Infection (MK-7655A-013)
Phase 3
Completed
- Conditions
- Bacterial Infections
- Interventions
- Drug: Imipenem+Cilastatin/RelebactamDrug: Imipenem+Cilastatin
- First Posted Date
- 2015-05-22
- Last Posted Date
- 2018-10-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 50
- Registration Number
- NCT02452047
© Copyright 2025. All Rights Reserved by MedPath